AIM ImmunoTech Net Worth
AIM ImmunoTech Net Worth Breakdown | AIM |
AIM ImmunoTech Net Worth Analysis
AIM ImmunoTech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AIM ImmunoTech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AIM ImmunoTech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AIM ImmunoTech's net worth analysis. One common approach is to calculate AIM ImmunoTech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AIM ImmunoTech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AIM ImmunoTech's net worth. This approach calculates the present value of AIM ImmunoTech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AIM ImmunoTech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AIM ImmunoTech's net worth. This involves comparing AIM ImmunoTech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AIM ImmunoTech's net worth relative to its peers.
Enterprise Value |
|
To determine if AIM ImmunoTech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AIM ImmunoTech's net worth research are outlined below:
| AIM ImmunoTech had very high historical volatility over the last 90 days | |
| AIM ImmunoTech has some characteristics of a very speculative penny stock | |
| AIM ImmunoTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 202 K. Reported Net Loss for the year was (28.96 M) with loss before taxes, overhead, and interest of (715 K). | |
| AIM ImmunoTech has about 27.05 M in cash with (21.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| AIM ImmunoTech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from Macroaxis: Should we be obtaining Aptorum or AIM ImmunoTech |
AIM ImmunoTech Quarterly Good Will |
|
AIM ImmunoTech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AIM ImmunoTech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AIM ImmunoTech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow AIM ImmunoTech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 15.91 M.Market Cap |
|
Project AIM ImmunoTech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.53) | (1.45) | |
| Return On Capital Employed | (3.42) | (3.25) | |
| Return On Assets | (1.34) | (1.28) | |
| Return On Equity | (3.25) | (3.09) |
When accessing AIM ImmunoTech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AIM ImmunoTech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AIM ImmunoTech's profitability and make more informed investment decisions.
Evaluate AIM ImmunoTech's management efficiency
AIM ImmunoTech has Return on Asset of (0.8004) % which means that on every $100 spent on assets, it lost $0.8004. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5479) %, meaning that it generated no profit with money invested by stockholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 7th of January 2025, Return On Tangible Assets is likely to grow to -1.45. In addition to that, Return On Capital Employed is likely to grow to -3.25. At this time, AIM ImmunoTech's Total Assets are very stable compared to the past year. As of the 7th of January 2025, Non Current Assets Total is likely to grow to about 8.5 M, while Other Assets are likely to drop 0.80.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.24 | 0.23 | |
| Tangible Book Value Per Share | 0.19 | 0.18 | |
| Enterprise Value Over EBITDA | (0.60) | (0.63) | |
| Price Book Value Ratio | 2.40 | 2.28 | |
| Enterprise Value Multiple | (0.60) | (0.63) | |
| Price Fair Value | 2.40 | 2.28 | |
| Enterprise Value | 19.1 M | 18.2 M |
The operational strategies employed by AIM ImmunoTech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 63.7471 | Revenue | Quarterly Revenue Growth 0.19 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AIM ImmunoTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on AIM ImmunoTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AIM ImmunoTech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AIM ImmunoTech time-series forecasting models is one of many AIM ImmunoTech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AIM ImmunoTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
AIM ImmunoTech Earnings per Share Projection vs Actual
AIM ImmunoTech Corporate Management
| Wayne Springate | Senior Vice President - Operations | Profile | |
| III Esq | Exec COO | Profile | |
| Ann Coverly | Director Coordinator | Profile | |
| MBA IV | Chief Officer | Profile | |
| Stewart Appelrouth | Director | Profile |
Already Invested in AIM ImmunoTech?
The danger of trading AIM ImmunoTech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AIM ImmunoTech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AIM ImmunoTech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AIM ImmunoTech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.50) | Revenue Per Share | Quarterly Revenue Growth 0.19 | Return On Assets | Return On Equity |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.